Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US-9630946-B2 · Apr 25, 2017 · US
Method for treating gefitinib resistant cancer
US10596162B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10596162-B2 |
| Application number | US-201615207349-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2016 |
| Priority date | Feb 3, 2005 |
| Publication date | Mar 24, 2020 |
| Grant date | Mar 24, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating gefitinib and/or erlotinib resistant non-small cell lung cancer having a T790M mutation in SEQ ID NO: 1 in a patient, comprising administering daily to the patient having gefitinib and/or erlotinib resistant non-small cell lung cancer having a T790M mutation in SEQ ID NO: 1 a pharmaceutical composition comprising a unit dosage of 2-500 mg of an irreversible EGFR inhibitor that covalently binds to cysteine 773 of the catalytic domain within the SEQ ID NO: 1 having a T790M mutation; wherein the irreversible EGFR inhibitor is not CL-387,785. 2. The method of claim 1 , wherein the irreversible EGFR inhibitor is selected from the group consisting of EKB-569, HKI-272 and HKI-357. 3. The method of claim 1 , wherein the irreversible EGFR inhibitor is HKI-272. 4. The method of claim 1 , wherein the irreversible EGFR inhibitor covalently binds to cysteine 805 in the ligand-binding pocket of ERBB2.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title
- A61K31/4709Primary
Non-condensed quinolines and containing further heterocyclic rings · CPC title
- A61K31/4706Primary
4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10596162B2 cover?
- The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a phar…
- Who is the assignee on this patent?
- Wyeth Llc, Massachusetts Gen Hospital
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).